← All Insights
Deep Tech / Industrial MRI
Orbem
A multi-vertical inspection platform with a single-vertical public identity.
A multi-vertical inspection platform with a single-vertical public identity.
Two forces are converging on the same problem in industrial quality control: regulatory mandates and AI-powered inspection. On one side, Germany mandated in-ovo egg sexing in 2022, and an EU-wide directive targeting 2027 is creating a compliance-driven replacement cycle across thousands of hatcheries. This is not optional adoption -- it is legislated demand. On the other side, food waste reduction targets across the EU and UK are pushing food producers toward upstream inspection: catching defects before commitment, before incubation, before shipment.
The non-destructive testing market exceeds $10B globally, and AI-powered food quality inspection is projected to surpass $1.5B by the late 2020s. Traditional inspection methods are either destructive (breaking the product to test it), surface-limited (optical and spectral systems that cannot see inside), or single-application (designed for one product type and unable to generalize). The gap in the market is a non-invasive inspection technology that can see inside biological matter at commercial speed, across multiple product types, without destroying the sample.
Orbem, a Munich Technical University spinout backed by a EUR55.5M Series B, has built exactly that: an AI-powered MRI platform that performs volumetric inspection of biological products at industrial throughput. The technology works on hatching eggs, tropical fruits, nuts, seeds, and emerging applications. The question is not whether the technology is real -- it is. The question is whether the world outside the hatchery industry knows it.
The competitive field in non-invasive biological inspection is defined not by who else does what Orbem does, but by the structural limitations of every alternative approach.
In Ovo (Netherlands, significant funding) uses hyperspectral imaging for in-ovo egg sexing. Non-invasive, which is good. But hyperspectral is surface-biased -- it detects signals from the egg's exterior rather than imaging the embryo volumetrically. Internal detection is limited compared to MRI. And the technology is single-vertical: designed for poultry and not extensible to fruits, nuts, or other biological products without fundamental retooling.
SELEGGT / AAT uses endocrine markers extracted from fluid in the egg. This is explicitly invasive -- it requires puncturing the egg to sample hormone levels. While the approach works for sex determination, the invasiveness introduces biosecurity risk and limits throughput at scale. Single-vertical.
QualySense / TOMRA (acquired) represents the optical and spectral inspection category. These systems are fast, well-established in food sorting, and genuinely non-invasive. But they inspect surfaces only. They cannot detect internal fat distribution, seed viability, embryo development, or structural anomalies hidden beneath the exterior. For quality parameters that matter inside the product, surface-based inspection is structurally blind.
Orbem is the only player with all three attributes simultaneously: fully volumetric (sees inside, not just the surface), completely non-invasive (no contact, no fluid extraction, no destruction), and multi-vertical (same imaging infrastructure, different AI models per application). Competitors may match one or two of these attributes. None match all three. And the EUR55.5M Series B provides the capital to scale commercial deployments before alternative approaches can close the volumetric gap.
B Clarity. "The world gets better when you see it from the inside out" is evocative but not immediately legible. A CEO encountering Orbem for the first time does not know what is being sold. "Inside out" is a metaphor, not a mechanism. The tagline invites curiosity rather than conviction. A hatchery operations director, a mango exporting company, and a pistachio processor all need to understand what Orbem replaces in their workflow within ten seconds. The current tagline requires them to read further to find out.
B+ Differentiation. The MRI angle is genuinely rare in the industrial inspection world -- no competitor leads with it. The volumetric capability (full internal imaging, not surface scanning) is structurally different from every alternative. But MRI surfaces in the messaging as a technology descriptor rather than the centerpiece of a platform identity. The moat is undersold. Orbem's competitive advantage is not incremental improvement over existing inspection -- it is a different category of information. That distinction deserves to be the positioning lead, not a supporting detail.
A- Believability. Strong. EUR55.5M Series B from credible investors. Munich Technical University spinout -- a signal of deep technical legitimacy. Commercial deployments at scale in the poultry industry. Multi-vertical expansion already underway (fruits, nuts, seeds). The credibility infrastructure is in place. Orbem does not need to earn trust. It needs to use that trust more aggressively in its positioning narrative.
The core tension: Orbem has built a platform, but it presents itself as a product. The technology works across poultry, tropical fruits, nuts, seeds, and emerging applications. The same imaging hardware runs different AI models per vertical -- that is the definition of a platform architecture. But the public identity is dominated by Genus Focus (the poultry product), and new verticals appear additive rather than proof of a deliberate platform thesis. Visitors to orbem.ai with no prior context leave thinking the company sells MRI machines to chicken farms.
Hatchery operators do not buy MRI machines. They buy the ability to stop culling male chicks before incubation begins. Mango exporters do not acquire imaging hardware. They buy the confidence to ship knowing internal defects have been caught. Pistachio processors do not want a volumetric scanner. They want certainty about fill, quality, and density before packing. Every Orbem buyer conversation should lead with the decision the technology enables, not the technology itself. "Every unit of biological product, inspectable before commitment" is a frame that scales across every current and future vertical without requiring the buyer to understand imaging physics. It makes the outcome the hero and MRI the mechanism -- which is how buyers actually think about their purchasing decision. "AI-powered MRI" as the positioning lead signals cost, complexity, and specialist equipment before any benefit is established. The outcome frame inverts that: benefit first, mechanism second.
Orbem's multi-vertical capability is the strongest evidence that this is a platform company, not a single-product company. But platform identity requires deliberate signaling. A named product family beyond Genus Focus tells enterprise buyers, investors, and potential partners that the poultry deployment was not a one-off -- it was the first proof point in a deliberate platform strategy. Naming creates category. When each vertical has its own named product (eggs, fruits, nuts, emerging), the pattern becomes visible: same infrastructure, different intelligence, each deployment proving the thesis. This distinction matters commercially because platform companies command different valuations, attract different partnership conversations, and build different competitive moats than single-product companies. Orbem already has the architecture of a platform. It needs the narrative of one.
A third opportunity involves anchoring the sustainability narrative with quantified customer evidence. The waste reduction story is compelling in the abstract but lacks the specificity that converts positioning into commercial references -- one published case study with concrete numbers would do more than any amount of general sustainability messaging. A fourth concerns building a vertical-expansion playbook that systematizes the go-to-market motion, not just the technology, but designing that playbook requires understanding which elements of the poultry sales motion are transferable and which are vertical-specific.
ProductBeacon monitors product leadership signals across European tech companies. Orbem appeared on our radar because the company has scaled to EUR55.5M Series B with a multi-vertical platform architecture, but its product leadership structure suggests the commercial positioning and GTM layer has not kept pace with the technical expansion. This analysis was created without any contact with the company, using only publicly available information (website, LinkedIn, press releases, job postings, and industry databases).
Analyst: Yohay Etsion, Managing Director, ProductBeacon. 17 years leading product organizations at NICE and Cognyte.
We build these analyses for companies where the technology has outgrown the public narrative. If your platform does more than your positioning says, we should talk.
Request a Diagnostic